Breaking News Instant updates and real-time market news.

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

09:12
10/23/19
10/23
09:12
10/23/19
09:12

Morgan Stanley 'surprised' by magnitude of Texas Instruments weakness

Morgan Stanley analyst Joseph Moore said he had expected weakness from Texas Instruments, but he was surprised at the magnitude and TI's comments citing weakness in nearly all end markets, in all geographies, and at "nearly every major customer." The analyst thinks the duration of this downcycle will "clearly be longer" than usual and doesn't expect TI to see year-over-year growth until the third quarter of 2020, at the earliest. Moore keeps an Equal Weight rating on TI shares and trimmed his price target for the stock to $109 from $110.

TXN Texas Instruments
$128.61

-2.32 (-1.77%)

10/23/19
RHCO
10/23/19
NO CHANGE
Target $122
RHCO
Hold
Texas Instruments price target lowered to $122 from $133 at SunTrust
SunTrust analyst William Stein lowered his price target on Texas Instruments to $122 and kept his Hold rating after its "weak but not surprising" Q3 results. The analyst notes that the quarter suggests that industry fundamentals will not bottom until Q4, stating that the guidance for next quarter was "especially surprising" and reflects further deceleration in sales while pushing the bottom of the cycle timing by one quarter. Stein adds that all of the company's end markets saw weakness, but Communications was "particularly bad", falling 20% from last quarter and 35% from last year.
10/23/19
OPCO
10/23/19
NO CHANGE
Target $120
OPCO
Outperform
Texas Instruments price target lowered to $120 from $140 at Oppenheimer
Oppenheimer analyst Rick Schafer lowered his price target for Texas Instruments to $120 from $140 following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/23/19
RBCM
10/23/19
NO CHANGE
Target $124
RBCM
Sector Perform
Texas Instruments price target lowered to $124 from $134 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Texas Instruments to $124 and kept his Sector Perform rating after its Q3 revenues came in a "tad below" expectations and Q4 guidance also missed forecasts. The analyst notes that the broad-based weakness in semiconductors remains evident, even though he sees the company as "one of the best-in-class" assets over the 5-10 year time frame. Steves adds that the valuation on Texas Instruments appears "full".
10/23/19
JEFF
10/23/19
NO CHANGE
Target $150
JEFF
Buy
Texas Instruments selloff on outlook should be bought, says Jefferies
Jefferies analyst Mark Lipacis lowered his price target for Texas Instruments to $150 from $170 saying that while the reduced Q4 outlook surprised him, historical trend and inventory analyses "tell us the weakness should be bought." The last two times Texas Instruments sales spiked materially below the trendline were in 2009 and 2016, and 12 months later the shares outperformed the S&P 500 Index index by 27% and 37%, Lipacis tells investors in a research note. He keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

SLNG

Stabilis Energy

$0.00

(0.00%)

11:52
11/12/19
11/12
11:52
11/12/19
11:52
Conference/Events
Stabilis Energy management to meet with Lake Street »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 19

    Nov

TNDM

TNDM

11:51
11/12/19
11/12
11:51
11/12/19
11:51
Conference/Events
Tandem Diabetes management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:50
11/12/19
11/12
11:50
11/12/19
11:50
General news
Treasury's $87 B 3- and 6-month bill sales were mixed »

Treasury's $87 B 3-…

IAC

IAC

$217.75

-2.42 (-1.10%)

11:49
11/12/19
11/12
11:49
11/12/19
11:49
Periodicals
IAC to invest to continue fast growth of mobile app unit, Axios says »

IAC has been building a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EBIX

Ebix

$37.16

-3.8 (-9.28%)

11:47
11/12/19
11/12
11:47
11/12/19
11:47
Hot Stocks
Ebix says in final stages of picking investment bank for payments business IPO »

Says "diligently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

11:45
11/12/19
11/12
11:45
11/12/19
11:45
General news
Breaking General news story  »

Richmond Federal Reserve…

11:45
11/12/19
11/12
11:45
11/12/19
11:45
General news
Breaking General news story  »

Richmond Federal Reserve…

BIO

Bio-Rad

$353.49

3.52 (1.01%)

11:39
11/12/19
11/12
11:39
11/12/19
11:39
Hot Stocks
Bio-Rad VP James Stark sells almost $300K in company shares »

Bio-Rad VP James Stark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:38
11/12/19
11/12
11:38
11/12/19
11:38
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:38
11/12/19
11/12
11:38
11/12/19
11:38
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

11:37
11/12/19
11/12
11:37
11/12/19
11:37
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

11:37
11/12/19
11/12
11:37
11/12/19
11:37
General news
8-Week Bill Announcement Offering Amount data reported »

8-Week Bill Announcement…

CIEN

Ciena

$38.04

0.26 (0.69%)

11:35
11/12/19
11/12
11:35
11/12/19
11:35
Options
Ciena put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$2.72

-0.205 (-7.01%)

11:25
11/12/19
11/12
11:25
11/12/19
11:25
Recommendations
Ocular Therapeutix analyst commentary  »

Ocular Therapeutix price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NVTA

Invitae

$16.90

-0.93 (-5.22%)

11:25
11/12/19
11/12
11:25
11/12/19
11:25
Options
Invitae call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHDN

Churchill Downs

$126.44

0.1 (0.08%)

11:25
11/12/19
11/12
11:25
11/12/19
11:25
Hot Stocks
Churchill Downs announces launch of retail sportsbook in Indiana »

Churchill Downs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.20

0.32 (0.68%)

, FGEN

FibroGen

$35.67

0.3 (0.85%)

11:25
11/12/19
11/12
11:25
11/12/19
11:25
Conference/Events
Cowen biotechnology analysts to hold an analyst/industry conference call »

Biotech Analysts Werber…

AZN

AstraZeneca

$47.20

0.32 (0.68%)

FGEN

FibroGen

$35.67

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 18

    Nov

  • 07

    Dec

ABBV

AbbVie

$87.72

2.08 (2.43%)

11:20
11/12/19
11/12
11:20
11/12/19
11:20
Hot Stocks
AbbVie reports 'positive' data from Phase 2/3 SELECT-AXIS 1 trial »

AbbVie announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AOBC

American Outdoor Brands

$7.87

-0.29 (-3.55%)

, VSTO

Vista Outdoor

$9.80

-0.1 (-1.01%)

11:17
11/12/19
11/12
11:17
11/12/19
11:17
Hot Stocks
Gunmakers slide as Supreme Court lets Sandy Hook families sue »

The U.S. Supreme Court…

AOBC

American Outdoor Brands

$7.87

-0.29 (-3.55%)

VSTO

Vista Outdoor

$9.80

-0.1 (-1.01%)

RGR

Sturm, Ruger

$44.50

-0.64 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/12/19
11/12
11:17
11/12/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/12/19
11/12
11:16
11/12/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$211.70

3.56 (1.71%)

, AMD

AMD

$36.96

0.66 (1.82%)

11:15
11/12/19
11/12
11:15
11/12/19
11:15
Recommendations
Nvidia, AMD analyst commentary  »

Nvidia price target…

NVDA

Nvidia

$211.70

3.56 (1.71%)

AMD

AMD

$36.96

0.66 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 09

    Dec

AGN

Allergan

$183.63

3.59 (1.99%)

11:15
11/12/19
11/12
11:15
11/12/19
11:15
Options
Allergan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/12/19
11/12
11:15
11/12/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
11/12/19
11/12
11:15
11/12/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.